Plain-English translation of NCT06810960 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →This is a 6-year safety study of LEQEMBI, a medication approved to treat early Alzheimer's disease. Researchers will collect real-world medical information from South Korean patients already receiving this treatment to monitor for specific side effects and understand how safe it is when used in everyday clinical practice.
Even after a medication is approved, doctors and companies need to keep watching how it performs in real patients over many years. This study helps ensure this medication remains safe and effective when used in everyday care outside of controlled clinical trials.
You likely qualify if…
You likely don't qualify if…
You would not need to do anything extra—the study uses medical information you're already sharing through the JOY-ALZ registry. Researchers will track your health information over 6 years to monitor for side effects related to the medication, particularly brain imaging changes. You'll continue receiving your treatment as your doctor normally prescribes it.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States
Enrollment target
~3,000 participants
Started
February 2025
Primary completion
September 2029
Age range
19 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Eisai Korea Inc. Medical department Serena SoYoun Kwon
Eisai Korea Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.